- Home
- API vs KYTX Comparison
API vs KYTX Comparison
Compare API & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- KYTX
- Stock Information
- Founded
- API 2013
- KYTX 2018
- Country
- API United States
- KYTX United States
- Employees
- API N/A
- KYTX N/A
- Industry
- API Computer Software: Prepackaged Software
- KYTX
- Sector
- API Technology
- KYTX
- Exchange
- API Nasdaq
- KYTX NYSE
- Market Cap
- API 223.6M
- KYTX 242.1M
- IPO Year
- API 2020
- KYTX 2024
- Fundamental
- Price
- API $4.39
- KYTX $4.35
- Analyst Decision
- API
- KYTX Buy
- Analyst Count
- API 0
- KYTX 5
- Target Price
- API N/A
- KYTX $23.40
- AVG Volume (30 Days)
- API 1.5M
- KYTX 237.0K
- Earning Date
- API 11-25-2024
- KYTX 11-13-2024
- Dividend Yield
- API N/A
- KYTX N/A
- EPS Growth
- API N/A
- KYTX N/A
- EPS
- API N/A
- KYTX N/A
- Revenue
- API $138,287,000.00
- KYTX N/A
- Revenue This Year
- API N/A
- KYTX N/A
- Revenue Next Year
- API $8.09
- KYTX N/A
- P/E Ratio
- API N/A
- KYTX N/A
- Revenue Growth
- API N/A
- KYTX N/A
- 52 Week Low
- API $1.65
- KYTX $4.32
- 52 Week High
- API $6.43
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- API 61.20
- KYTX 33.83
- Support Level
- API $4.00
- KYTX $5.01
- Resistance Level
- API $5.47
- KYTX $5.62
- Average True Range (ATR)
- API 0.53
- KYTX 0.39
- MACD
- API 0.11
- KYTX -0.03
- Stochastic Oscillator
- API 60.73
- KYTX 2.19
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.